Literature DB >> 3720202

Droplet size distributions of nebulised aerosols for inhalation therapy.

S P Newman, P G Pellow, S W Clarke.   

Abstract

Jet nebulisers are used commonly for aerosol therapy in patients with asthma and bronchitis, but the manufacturers' information regarding aerosol droplet size is often inadequate. In this study, mass median diameter, geometric standard deviation and the percentage of the aerosol mass contained within 'respirable' (less than 5 micron diameter) droplets have been measured for 11 brands of jet nebuliser with a solution of hypertonic (7%) saline at compressed gas flow rates between 6 and 121 min-1 using a laser light scattering device (Malvern Instruments 2600 HSD analyser). There was a considerable variation in droplet size between the nebuliser brands and among nebulisers of the same brand. Droplet size decreased with increasing compressed gas flow rate. These findings suggest that the quantity of drug available to the patient depends on the individual nebuliser used, and upon the pressure and flow of the compressed gas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720202     DOI: 10.1088/0143-0815/7/2/004

Source DB:  PubMed          Journal:  Clin Phys Physiol Meas        ISSN: 0143-0815


  17 in total

Review 1.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

2.  A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions.

Authors:  Q A Summers; M R Nesbit; R Levin; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

4.  Drug delivery from jet nebulisers.

Authors:  M L Everard; A R Clark; A D Milner
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

5.  Nebulised pentamidine as treatment for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  Q Summers
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

6.  Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance.

Authors:  R C Hubbard; M A Casolaro; M Mitchell; S E Sellers; F Arabia; M A Matthay; R G Crystal
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 7.  Aerosol therapy in AIDS.

Authors:  S P Newman; A K Simonds
Journal:  Lung       Date:  1990       Impact factor: 2.584

8.  Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation.

Authors:  M L Everard; J G Hardy; A D Milner
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

Review 9.  Aerosols for therapy and diagnosis.

Authors:  M J O'Doherty; R F Miller
Journal:  Eur J Nucl Med       Date:  1993-12

Review 10.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.